In Vivo Pharmacology

Fertility


We offer models specialized models for assessment of products with applications in fertility related disorders. These include the following

  • Estrogenic activity
    Model Assessment of Estrogenic potential using ovariectomized animals
    Test system Mouse
    Method
    Perform surgical ovariectomyAdministration of test itemHumane sacrifice and measurement of uterus weightUterine HistopathologyReference Drug: Estradiol
    End points
    • Uterine WeightUterine and Body weight RatioUterotrophic ActivityGrading of the test item for its estrogenic potential
    X
  • Models for Dysmenorrhea
    Model Whole Blood PGE2 Inhibition assay
    Test system Human Whole Blood
    Method
    • Collection & heparinization of healthy female volunteer blood
    • Pretreatment with test item
    • LPS mediated induction of PGE2 & quantitation
    • Reference Drug - Naproxen or client defined reference product
    End points
    • % PGE2 Inhibition
    • IC50Values of PGE2 inhibition
    • Grading of the test item for its anti –dysmenorrheal potential
    X
  • PCOD
    Model Evaluation of test item against morphological and metabolic abnormalities related to Polycystic Ovary Disease (PCOD)
    Test system Female Wistar Rat; 3-4 week old
    Method
    • Induction of PCOD by giving 1 mg/kg p.o. of Letrazole daily for 28 days (Except G1).
    • After induction period Test and standard drug will be administered for 8 estrous cycles.
    • Daily vaginal smear will be withdrawn throughout the dosing period for the determination of disturbances in estrous cycle.
    • Feed consumption, Body weight record, estrous cycle will be monitored throughout the experimental period.
    • Blood will be withdrawn after 24hrs of last dose between 9:00 hrs to 12:00 hrs and plasma level of testosterone, progesterone & estradiol will be assayed FSH & LH will be estimated with RIA kit.
    • At the end of experimental period, all animal will be scarified and Ovary and Uterus weight change will be determined. Ovary and uteruses will be subjected to histopathological evaluation.
    End points
    • Feed consumption & Body weight record
    • Daily vaginal smears for determination of estrous cycle.
    • OGTT for G2 and G4 before and after treatment. (n=6)
    • Euglycemic clamp experiment for G2 and G4 before and after treatment. (n=3)
    • Blood Biochemistry
    • Plasma testosterone, estrogen & progesterone levels
    • Glucose, Triglyceride, HDL, total cholesterol and Leptin level
    • Luteinizing hormone (LH) and Follicular Stimulating Hormone (FSH)
    • Histopathological evolution
    • Ovary histopathology for determination of ovary size, follicle size, area of largest follicle and thickness of follicle wall.
    X
  • Assement of mating potential
    Model Screening of compounds on mating behavior in male rats using Sildenafil Citrate as Control.
    Test system Wistar Rat, 10-12 weeks
    Method
    • Healthy and sexually experienced male Wistar rats is selected for the study
    • Male Animals is brought to the experiment room and exposed to dim light at the stipulated time of testing daily before the mating behaviour test (2 weeks)
    • The female animals is artificially brought into oestrus (heat)(Day 14 & 15)
    • Group G1 served as normal control (vehicle; p.o.) and G2 is treated with Sildenafil citrate (10 mg/kg, p.o.) on day 15; 1 h prior to the commencement of the experiment
    • One receptive female is introduced into each cage of one male.
    • Observation of mating behaviour is immediately commenced and continued for 20 minutes by using remote video.
    • Serum Testosterone is estimated after the test
    End points
    • Mating behaviour parameters
    • Serum Testosterone levels
    X